文献速递白血病造血干细胞移植与细胞治疗

H3K79me2/3调控MLL-AF4白血病中PROM1/CD133增强子-启动子互作

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.
PubMed 文献 · Leukemia · 2020-04-02

该研究探讨MLL-AF4融合蛋白通过DOT1L介导的H3K79me2/3修饰调控PROM1/CD133表达的机制。发现MLL-AF4直接结合PROM1基因内H3K79me2/3增强子元件,促进PROM1与邻近TAPT1基因的增强子-启动子互作,从而激活CD133表达,且CD133对白血病细胞生长必需。

要点

  • MLL-AF4直接结合PROM1基因内H3K79me2/3增强子元件调控CD133表达
  • PROM1与TAPT1双基因座调控在白血病中表达强相关
  • CD133表达对MLL-AF4白血病细胞生长必需

核心结论

  • PROM1/CD133在MLL-AF4白血病中异常表达由基因内H3K79me2/3增强子元件介导,并依赖增强子-启动子互作。
  • CD133表达对白血病细胞生长必需,为潜在治疗靶点。

研究设计与样本

  • 基于MLL-AF4白血病细胞的机制研究,采用染色质互作与基因表达分析。
  • 对比PROM1/CD133表达与非表达细胞中PRC2结合及TAPT1表达差异。

主要发现

  • MLL-AF4直接结合PROM1基因内H3K79me2/3增强子元件(KEE),增强PROM1与TAPT1间增强子-启动子互作。
  • PROM1与TAPT1表达在白血病中呈强相关。
  • PROM1/CD133非表达细胞中PRC2结合抑制PROM1 locus,伴TAPT1表达降低,部分因与PROM1互作丢失。

临床怎么用

  • CD133可作为MLL-AF4白血病潜在靶点,但需进一步临床验证。
  • H3K79me2/3增强子元件调控机制提示DOT1L抑制可能影响CD133表达。

局限性

  • 研究为体外细胞机制分析,未提供临床样本或体内疗效数据。
  • 未报告具体样本量、统计阈值或剂量信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The most common MLLr produces an MLL-AF4 fusion protein. MLL-AF4 promotes leukemogenesis by activating key target genes, mainly through recruitment of DOT1L and increased histone H3 lysine-79 methylation (H3K79me2/3). One key MLL-AF4 target gene is PROM1, which encodes CD133 (Prominin-1). CD133 is a pentaspan transmembrane glycoprotein that represents a potential pan-cancer target as it is found on multiple cancer stem cells. Here we demonstrate that aberrant PROM1/CD133 expression is essential for leukemic cell growth, mediated by direct binding of MLL-AF4. Activation is controlled by an intragenic H3K79me2/3 enhancer element (KEE) leading to increased enhancer-promoter interactions between PROM1 and the nearby gene TAPT1. This dual locus regulation is reflected in a strong correlation of expression in leukemia. We find that in PROM1/CD133 non-expressing cells, the PROM1 locus is repressed by polycomb repressive complex 2 (PRC2) binding, associated with reduced expression of TAPT1, partially due to loss of interactions with the PROM1 locus. Together, these results provide the first detailed analysis of PROM1/CD133 regulation that explains CD133 expression in MLLr ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Godfrey L, Crump NT, O'Byrne S, et al. H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. Leukemia. 2020. PMID: 32242051. doi:10.1038/s41375-020-0808-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。